Multiple sclerosis drugs: How much bang for the buck?

The Lancet Neurology

Volumn 14, Issue 5, 2015, Pages 460-461

  Stüve, Olaf ^a,b,c   Cutter, Gary R ^d  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; BETA INTERFERON; IMMUNOLOGIC FACTOR; PEPTIDE;

CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; EXPANDED DISABILITY STATUS SCALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NOTE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELAPSE; REMISSION; UNITED KINGDOM; COST BENEFIT ANALYSIS; FEMALE; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; TREATMENT OUTCOME;

EID: 84928055403     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00016-2     Document Type: Note

References (7)

1. Uitdehaag BM, Barkhof F, Coyle PK, et al. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin 2011, 27:1529-1537.
2. Palace J, Duddy M, Bregenzer T, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol 2015, published online April 2. http://dx.doi.org/10.1016/S1474-4422(15)00018-6.
3. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003, 326:522.
4. Himmelstein DU, Thorne D, Warren E, Woolhandler S Medical bankruptcy in the United States, 2007: results of a national study. Am J Med 2009, 122:741-746.
5. Stachowiak J Multiple sclerosis drug prices. Whoa. . . (accessed March 24, 2015). http://ms.about.com/b/2009/07/21/multiple-sclerosis-drug-prices-whoa.htm.
6. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012, 308:247-256.
7. Karim ME, Gustafson P, Petkau J, et al. Marginal structural Cox models for estimating the association between beta-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol 2014, 180:160-171.